- Home
- WOOF vs SYRE Comparison
WOOF vs SYRE Comparison
Compare WOOF & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOOF
- SYRE
- Stock Information
- Founded
- WOOF 1965
- SYRE 2013
- Country
- WOOF United States
- SYRE United States
- Employees
- WOOF N/A
- SYRE N/A
- Industry
- WOOF Other Specialty Stores
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- WOOF Consumer Discretionary
- SYRE Health Care
- Exchange
- WOOF Nasdaq
- SYRE Nasdaq
- Market Cap
- WOOF 986.5M
- SYRE 1.1B
- IPO Year
- WOOF 2021
- SYRE 2016
- Fundamental
- Price
- WOOF $3.16
- SYRE $23.46
- Analyst Decision
- WOOF Hold
- SYRE Strong Buy
- Analyst Count
- WOOF 11
- SYRE 5
- Target Price
- WOOF $3.91
- SYRE $55.75
- AVG Volume (30 Days)
- WOOF 2.1M
- SYRE 1.4M
- Earning Date
- WOOF 12-04-2025
- SYRE 11-06-2025
- Dividend Yield
- WOOF N/A
- SYRE N/A
- EPS Growth
- WOOF N/A
- SYRE N/A
- EPS
- WOOF N/A
- SYRE N/A
- Revenue
- WOOF $6,045,495,000.00
- SYRE N/A
- Revenue This Year
- WOOF N/A
- SYRE N/A
- Revenue Next Year
- WOOF $0.98
- SYRE N/A
- P/E Ratio
- WOOF N/A
- SYRE N/A
- Revenue Growth
- WOOF N/A
- SYRE N/A
- 52 Week Low
- WOOF $2.28
- SYRE $10.91
- 52 Week High
- WOOF $6.29
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- WOOF 35.06
- SYRE 63.91
- Support Level
- WOOF $3.10
- SYRE $23.52
- Resistance Level
- WOOF $3.87
- SYRE $25.06
- Average True Range (ATR)
- WOOF 0.16
- SYRE 1.24
- MACD
- WOOF -0.06
- SYRE 0.03
- Stochastic Oscillator
- WOOF 9.74
- SYRE 66.75
About WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.